drugset / Trial / NCT07512076
A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II, single-centre, pragmatic, non-randomized, dose escalation study to evaluate optimal dose levels of enzalutamide in elderly patients using pharmacokinetic blood sampling concentrations.
Timeline
- Start
- 2026-04
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 40 mg | — |
| Subject | Enzalutamide | Other / unclassified | 80 mg | — |
| Subject | Enzalutamide | Other / unclassified | 120 mg | — |
| Subject | Enzalutamide | Other / unclassified | 160 mg | — |